ProfileGDS5678 / 1443961_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 63% 71% 61% 62% 69% 70% 63% 63% 64% 62% 64% 63% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.903565
GSM967853U87-EV human glioblastoma xenograft - Control 23.7493163
GSM967854U87-EV human glioblastoma xenograft - Control 34.4610271
GSM967855U87-EV human glioblastoma xenograft - Control 43.5848161
GSM967856U87-EV human glioblastoma xenograft - Control 53.6634562
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2146869
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3978570
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7489763
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7640463
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8467864
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6734662
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8053264
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7877363
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7838463